Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II randomized double-blind placebo-controlled study of SCTC21C in IgA nephropathy
CTR20244343Phase 2Active
- Sponsor
- Sinocelltech Group Limited
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in IgA nephropathy (IgAN) comparing SCTC21C with Placebo (2 arms). Primary endpoints: Safety and tolerability and Change rate in urine protein-to-creatinine ratio. Started Feb 2025; status: active.
02
Drugs
SCTC21C
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20244343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244343.